← Eichor
Condition: Philadelphia Chromosome Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Philadelphia Chromosome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431EWALL-PH OBSERVARTORY 2022
Phase N/A · 23 location(s) · Versailles Hospital · NCT07684131Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Phase 2 · 85 location(s) · Goethe University · NCT06061094Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06387121Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromoso
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05660473Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07493161Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07250087Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03589729Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
Phase 1/Phase 2 · 1 location(s) · Novartis Pharmaceuticals · NCT07387926Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
Phase 2 · 1 location(s) · University of Washington · NCT07224100Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acut
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06308588ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid L
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05007873Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07564453A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chr
Phase N/A · 54 location(s) · Novartis Pharmaceuticals · NCT07549516Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Phase 2 · 13 location(s) · Grupo Español de Enfermedades Mieloproliferativas Crónicas P · NCT07394153Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06220487Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resis
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01746836Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481228Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin
Phase 2 · 1 location(s) · University of Washington · NCT06738368A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Phase 3 · 18 location(s) · Il-Yang Pharm. Co., Ltd. · NCT03459534A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Phase N/A · 1 location(s) · Pfizer · NCT06297161
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.